The present disclosure relates to a method for producing a purified cannabaceae biomass extract, wherein a crude alcoholic cannabaceae biomass extract comprising at least two cannabinoid compounds in an alcoholic solvent is circulating through a powdered layer of activated carbon and the purified cannabaceae biomass extract is recovered with a ratio of cannabinoid compounds in the purified cannabaceae biomass extract is higher than the ratio of the cannabinoid compounds in the crude alcoholic cannabaceae biomass extract.

Disclosed is an industrial extraction method of cannabidiol, pertaining to the field of medicine and chemical industry. The present invention aims to resolve the problems of difficulty in wax removal, low extraction rate of cannabidiol, and excessively high content of tetrahydrocannabinol during extraction using conventional solvents in the prior art. The extraction method employs raw material pretreatment, granulation, extraction, liquid-liquid extraction, decolorization, concentration, and other processes, such that wax removal from an extracted liquid is improved, the purity of a crude cannabidiol oil can be increased to 60%, and 40% of tetrahydrocannabinol can be removed. The method has high extraction yields and low costs, and can be implemented in large-scale industrial production.

The present invention relates to methods for treating cannabis biomass in order to isolate tetrahydrocannabinolic acid (THCA). In another aspect, the present invention relates to a process that involves purification followed by extraction of cannabis biomass to isolate and improve yields of high-purity crystalline extracts.

The present invention relates to methods for treating cannabis biomass in order to isolate tetrahydrocannabinolic acid (THCA). In another aspect, the present invention relates to a process that involves purification followed by extraction of cannabis biomass to isolate and improve yields of high-purity crystalline extracts.

Synthetic cannabinoid compounds for treatment of pain and anxiety by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure:

##STR00001##

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

A method of making CBD concentrate or CBD Isolate comprises (a) milling a raw material; (b) contacting the milled raw material with an extraction solvent and separating a solid waste material to form a filtered extract; (c) concentrating the filtered extract; (d) washing the concentrated extract to form an organic phase and an aqueous phase; (e) separating the aqueous phase from the organic phase to form a washed extract; (f) removing an organic solvent from the washed extract to form a concentrated washed extract; (g) decarboxylating the concentrated washed extract; (h) vacuum distilling the decarboxylated extract to form a distillate; (i) dewaxing the distillate to form a post-dewax filtrate; (j) applying a vacuum to the post-dewax filtrate to form a post-dewax concentrate; (k) degassing the post-dewax concentrate; and (l) vacuum distilling the degassed concentrate to form a CBD concentrate.

A method of making CBD concentrate or CBD Isolate comprises (a) milling a raw material; (b) contacting the milled raw material with an extraction solvent and separating a solid waste material to form a filtered extract; (c) concentrating the filtered extract; (d) washing the concentrated extract to form an organic phase and an aqueous phase; (e) separating the aqueous phase from the organic phase to form a washed extract; (f) removing an organic solvent from the washed extract to form a concentrated washed extract; (g) decarboxylating the concentrated washed extract; (h) vacuum distilling the decarboxylated extract to form a distillate; (i) dewaxing the distillate to form a post-dewax filtrate; (j) applying a vacuum to the post-dewax filtrate to form a post-dewax concentrate; (k) degassing the post-dewax concentrate; and (l) vacuum distilling the degassed concentrate to form a CBD concentrate.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

A pharmaceutical composition containing an effective amount of cannabidiol (CBD) for use in treating or preventing a heart condition, along with related methods and uses. The heart conditions include heart failure, acute myocarditis, toxicity caused by anti-cancer therapies, acute pericarditis, cardiac sarcoidosis, inflammatory cardiomyopathy, and atherosclerosis and related uses and methods. The disclosure shows CBD to be effective in (i) reducing cardiac hypertrophy; (ii) reducing cardiac fibrosis; (iii) reducing the level of BNP; (iv) reducing the level of cytokine IL1β; (v) reducing the level of cytokine IL6; (vi) reducing the level of CD69; (vii) increasing the level of cytokine IL10, and (viii) combinations thereof. The composition is preferably adapted for parenteral administration.